Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabiana Ciciriello has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ecological Patterns of Gut Microbiota During Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis

    by Lorenza Putignani, Fabiana Ciciriello, Luigia Turco, Federica Del Chierico, Chiara Marangelo, Matteo Scanu, Francesca Toto, Enza Montemitro, Valentino Bezzerri, Ersilia Fiscarelli, et al.

    Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations. The elexacaftor/tezacaftor/ivacaftor (ETI) drug combination has markedly improved CF outcomes; however, its impact on gut microbiota (GM) dysbiosis remains poorly investigated. Herein, we examined potential longitudinal effects of ETI treatment on six CF patients’ GM before therapy (T0), and after 6 (T1) and 12 months (T2). Patients’ stools were analyzed using 16S rRNA metataxonomy, and GM profiling was characterized by alpha diversity, performed using the Shannon–Weiner, Simpson, and Chao1 indices; beta diversity, based on Bray–Curtis distance; and taxonomic patterns through multivariate and univariate analyses. A longitudinal exploratory assessment of the GM composition of CF patients at T0, T1, and T2 was performed. At baseline, CF patients displayed a distinct genus-level microbial signature compared with healthy controls, including Veillonella_A, Haemophilus_D_735815, Fusobacterium_C, Ruminococcus_B, and Blautia_A_141780. During ETI treatment, alpha diversity showed no significant transient increase at T1 followed by a decrease at T2. Taxonomic profiles showed marked inter-individual heterogeneity. Exploratory longitudinal analyses, assessed by the Friedman test, identified temporal variation in 11 bacterial genera: CAG-177, Clostridium_AP, Coprococcus_A_121497, Copromonas, and Muricomes_149725, showed a progressive decrease in relative abundance from T0 to T2; Haemophilus_D_734546, Eubacterium_B, Lachnoanaerobaculum, Moraxella_C_651924, and Neisseria_563205 displayed a transient increase at T1, followed by a decrease at T2; and Lactococcus_A_346120 showed a transient decrease at T1 followed by an increase at T2. Progressive depletion and transient changes or recovery of bacterial taxa may only represent a rough idea of the ecological changes in the gut microbiota observed during the course of ETI therapy. Longitudinally studies based on large cohorts of CF patients are mandatory to properly interpret these very preliminary results and to search for actual ETI-induced microbiome effects.

  • Open Access

    Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence

    by Alessandra Boni, Chiara Vassallo, Fabiana Ciciriello, Luca Cristiani, Alessandro Mancini, Luigi Zucaro, Sonia Graziano, Bianca Maria Goffredo, Federico Alghisi, Massimiliano Raponi, et al.

    Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastrointestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Seven relevant studies were identified and qualitatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing confirmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated improvement in bowel dilatation and hyperchogenity. The infant was delivered at 36 + 2, passed meconium spontaneously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence the early trajectory of CF, potentially by preventing MI and potentially delaying the progression to pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.


  • Open Access

    Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Review of the Emerging Evidence

    by Alessandra Boni, Chiara Vassallo, Fabiana Ciciriello, Luca Cristiani, Alessandro Mancini, Luigi Zucaro, Sonia Graziano, Bianca Maria Goffredo, Federico Alghisi, Massimiliano Raponi, et al.

    Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastro-intestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in-utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Ten relevant studies were identified and quali-tatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing con-firmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated im-provement in bowel dilatation and hyperchogenity. The infant was delivered at 36 +2, passed meconium spontane-ously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence early trajectory of CF, potentially by preventing MI and preserve pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.

  • Open Access

    Mutations with residual CFTR function are associated with better glucose tolerance and insulin secretion in people with Cystic fibrosis

    by Fabiana Ciciriello, Andrea Foppiani, Federica Sileo, Federico Alghisi, Maria Chiara Russo, Laura Elisabetta Claut, Arianna Bisogno, Stefano Costa, Maria Cristina Lucanto, Vincenzina Lucidi, et al.

  • COVID-19 in people with Cystic Fibrosis beyond the pre-omicron era: a prospective study with a specific focus on long COVID

    by Carla Colombo, Paola Medino, Marco Cipolli, Francesca Lucca, Giulia Cucchetto, Federico Alghisi, Fabiana Ciciriello, Angela Sepe, Camilla Romano, Giovanni Taccetti, et al.

  • Open Access

    Height Velocity in Pediatric Cystic Fibrosis Under Triple CFTR Modulator Therapy: A Real-Life Monocentric Experience

    by Alessandra Boni, Francesco D’aniello, Grazia Ubertini, Marco Cappa, Fabiana Ciciriello, Fabio Majo, Luca Cristiani, Federico Alghisi, Enza Montemitro, Sergio Bella, et al.

    Background/Objectives: Cystic fibrosis (CF) is a multi-system disorder characterized by chronic respiratory failure, malnutrition, and impaired growth. Achieving linear growth above the 50th percentile is associated with better pulmonary outcomes. Since October 2022, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has been approved in Italy for children aged ≥6 years. However, data on its impact on height velocity (HV) remain lacking. This study aims to evaluate growth patterns by HV and explore differences according to the CFTR variant genotype. Methods: We conducted a prospective single-center study at the CF Unit of Bambino Gesù Children’s Hospital involving 24 children aged 6–11 years eligible for ETI treatment. Baseline assessments included height, weight, body mass index (BMI), bone mineral density (BMD), body composition (via bioelectrical impedance analysis, BIA), and muscle strength (one-minute sit-to-stand test (1STST)). Height, weight, HV, and BMI standard deviation scores (SDS) were calculated for the 6 months before and after ETI initiation. Results: The mean age of the cohort was 8.7 ± 1.9 years (F/M: 12/12), with most patients naïve to CFTR modulators. A significant increase in HV was observed post-ETI: from 4.2 ± 2.0 cm/year (−1.96 ± 2.4 SDS) in the 6 months before treatment to 7.1 ± 3.0 cm/year (+1.5 ± 3.7 SDS) after treatment initiation (p < 0.0001). Patients with F508del/minimal function (F/MF) genotypes (n = 11) showed significantly greater HV compared to those with F508del/F508del (F/F, n = 5) and F508del/residual function (F/RF, n = 8) genotypes (p < 0.0001). No significant differences were observed among genetic groups in baseline BMD or lean mass. Conclusions: ETI treatment significantly and rapidly improves HV in children with CF, particularly in those with F/MF genotypes. These findings underscore the role of CFTR modulator therapy in promoting linear growth, a key indicator of health in pediatric CF populations.


  • Open Access

    Development and Validation of a New LC-MS/MS Method for Simultaneous Quantification of Ivacaftor, Tezacaftor and Elexacaftor Plasma Levels in Pediatric Cystic Fibrosis Patients

    by Alessandro Mancini, Raffaele Simeoli, Luca Cristiani, Sara Cairoli, Fabiana Ciciriello, Alessandra Boni, Federico Alghisi, Chiara Rossi, Giacomo Antonetti, Carlo Dionisi Vici, et al.

    Background: “CFTR modulators” (also named “caftor”) have been developed and introduced into clinical practice to improve the functionality of defective CFTR protein. Therapeutic drug monitoring (TDM) is not currently used for CFTR modulators in routine clinical practice and there is still much to learn about the pharmacokinetic/pharmacodynamic (PK/PD) and the safety profiles of these drugs in a real-world setting. Moreover, therapeutic ranges are not yet available for both pediatric and adult cystic fibrosis (CF) patients. Methods: A new and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for contemporary quantification of ivacaftor (IVA), tezacaftor (TEZ) and elexacaftor (ELX) in plasma samples has been developed and validated. The clinical performance of our method has been tested on samples collected during the routine clinical practice from n = 25 pediatric patients (aged between 7 and 17 years) affected by cystic fibrosis. This LC-MS/MS method has been validated according to ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines for the validation of bioanalytical methods. Results: Our method fulfilled ICH guidelines in terms of accuracy, precision, selectivity, specificity and carry-over. Intra- and inter-day accuracy and precision were ≤15%. The 9-day autosampler stability was 90–100% for TEZ and ELX; meanwhile, it fell to 76% for IVA. An injection volume of 1 µL and a wider quantification range (0.1–20 µg/mL) represent a novelty of our method in terms of sensitivity and fields of application. Finally, the evaluation of PK exposure parameters for IVA revealed strong agreement with previously published reports and with results from the summary of product characteristics (SmPCs). Conclusions: This method could be adopted to contemporarily measure ELX/TEZ/IVA plasma levels for both PK studies and monitor therapy compliance, especially in case of poor or partial responses to treatment, or to evaluate drug–drug interactions when multiple concomitant medications are required. Considering also the high cost burden of these medications to the health system, a TDM-based approach could facilitate more cost-effective patient management.


  • Open Access

    Phosphatidylinositol 5-Phosphate-Loaded Apoptotic Body-Like Liposomes for Mycobacterium abscessus Infection Management in Patients With Cystic Fibrosis

    by Tommaso Olimpieri, Noemi Poerio, Fabio Saliu, Nicola I Lorè, Fabiana Ciciriello, Greta Ponsecchi, Marco M D’aNdrea, Federico Alghisi, Daniela M Cirillo, Maurizio Fraziano

    The study investigates therapeutic strategies for managing chronic Mycobacterium abscessus infections, particularly in people with cystic fibrosis (PWCF) who are ineligible for standard elexacaftor, tezacaftor, ivakaftor (ETI) treatments. Apoptotic body-like liposomes loaded with phosphatidylinositol 5-phosphate (ABL/PI5P) were tested in vitro in M. abscessus-infected macrophages from PWCF as potential treatment. ABL/PI5P reduced intracellular bacterial viability and showed enhanced effects on a M. abscessus clinical strain when combined with amikacin. Notably, ABL/PI5P was effective on macrophages from PWCF not receiving ETI therapy. The findings suggest ABL/PI5P liposomes as a promising alternative or adjunct therapy, especially for those who cannot access ETI treatment, warranting further clinical investigation.


  • Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls

    by Suzanne Kroes, Marlou C. Bierlaagh, Juliet W. Lefferts, Alessandra Boni, Danya Muilwijk, Carla Viscomi, Natascha D.A. Keijzer-Nieuwenhuijze, Luca Cristiani, Paul J. Niemöller, Tibo F. Verburg, et al.


  • Covid-19 in cystic fibrosis patients compared to the general population: Severity and virus-host cell interactions

    by Fabiana Ciciriello, Francesco Panariello, Paola Medino, Arianna Biffi, Federico Alghisi, Chiara Rosazza, Patrizia Annunziata, Valentina Bouchè, Antonio Grimaldi, Daniela Guidone, et al.